FDA approves AZ's Bevespi Aerosphere for COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Bevespi Aerosphere ( PT003) for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Bevespi Aerosphere delivers long-acting muscarinic antagonist (LAMA) glycopyrrolate ( PT001) and long-acting adrenergic receptor beta 2 agonist (LABA) formoterol fumarate (PT005) via a hydrofluoroalkane metered-dose inhaler. Spokesperson Blake Swagler said AZ intends to launch the product in 1Q17, but has not yet set a price. ...